FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback